# Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

> **NCT05705401** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 1300 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **RADIATION:** Standard of Care Adjuvant Breast Radiation
- **DRUG:** Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation

## Key facts

- **NCT ID:** NCT05705401
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-19
- **Primary completion:** 2034-02-01
- **Final completion:** 2037-02-01
- **Target enrollment:** 1300 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705401, "Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05705401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*